Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
lunes, septiembre 28
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Artelo Biosciences Inc
ARTL
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$4.50
-0.04
-0.88%
Últ. Act.: Sep 28, 9:29 AM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Informe de acciones
Artelo Biosciences Financials
Artelo Biosciences (ARTL) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Artelo Biosciences Q2 EPS $(0.89) Up From $(16.83) YoY
Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(0.89) per share. This is a 94.71 percent increase over losses of $(16.83) per share from the same period last year.
Benzinga Newsdesk
PRO
Artelo Biosciences Q1 EPS $(4.00) Misses $(1.57) Estimate
Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(4.00) per share which missed the analyst consensus estimate of $(1.57) by 154.78 percent. This is a 69.14 percent increase over losses of $(12.96) per share
Benzinga Newsdesk
PRO
Artelo Biosciences Q4 EPS $1.38 Beats $(1.57) Estimate
Artelo Biosciences (NASDAQ:ARTL) reported quarterly earnings of $1.38 per share which beat the analyst consensus estimate of $(1.57) by 187.9 percent. This is a 119.66 percent increase over losses of $(7.02) per share
Benzinga Newsdesk
PRO
Artelo Biosciences Q3 EPS $(3.97) Misses $(0.82) Estimate
Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(3.97) per share which missed the analyst consensus estimate of $(0.82) by 384.15 percent. This is a 89.05 percent decrease over losses of $(2.10) per share
Benzinga Newsdesk
Nasdaq Gains Over 100 Points; Science Applications Shares Fall After Q2 Results
Avi Kapoor
PRO
Artelo Biosciences Q2 EPS $(5.61) Misses $(4.19) Estimate
Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(5.61) per share which missed the analyst consensus estimate of $(4.19) by 33.89 percent. This is a 24.67 percent decrease over losses of $(4.50) per share
Benzinga Newsdesk
Privacy Manager